Feed / BEAM

Beam Therapeutics Inc.

BEAM

Healthcare · 29.78 +4.9% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Beam Therapeutics Inc.'s move is being confirmed by its market group.

BEAM accounts for 3.6% of the group's measured movement across 6.0 effective names. raw member direction is mixed; 6 of 8 SPY-adjusted paths align to the downside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveAligned contributor#7 of 8 by movement share
Group movement share3.6%Absolute path energy—not portfolio weight
Relative path-0.44%aligned
Effective breadth6.0 / 8broad
Relative alignment6/8downside path · 1 counter-moving
Capital-flow agreement15%not yet clean
SEQUENCE READ

BBIO, ARWR, CGON moved materially before BEAM. BEAM crossed its material path threshold at 12:05 ET, 60 minutes after the first measured mover.

EVIDENCE COVERAGE

5 of 8 members in Gene Editing Therapies are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 6 of 8 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as RLYB begins moving with the group.

Invalidation: The live read weakens if participation falls to 2 of 8 members or fewer.

Watch this read

Who this business touches

The relationships behind BEAM

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

LLYEli Lilly and CompanypartnerMay 7, 2026

Verve Therapeutics and Eli Lilly and Company We are party to a license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, pursuant to which we granted Verve exclusive worldwide licenses under our base editing technologies for human th…

BMYBristol-Myers Squibb CompanypartnerMay 7, 2026

Orbital Therapeutics and Bristol Myers Squibb Company We are party to a license agreement, or the Orbital Agreement, with Orbital, pursuant to which each of us have granted the other non-exclusive licenses to certain technology that is necessary or reasonably…

Depended on by

SANASana Biotechnology, Inc.partnerMay 11, 2026

Our ex vivo and in vivo technologies represent an aggregation of years of innovation and technology from multiple academic institutions and companies, including hypoimmune technology licensed from the President and Fellows of Harvard College (Harvard) and The…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

BEAM is currently a Follower in the organic co-movement group Gene Editing Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.